# InxMed

Source: https://onco.cc/companies/inxmed/  
OnCo record `inxmed` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

InxMed is a Shanghai biotechnology company developing IN10018 (ifebemtinib), a focal adhesion kinase inhibitor, which is in a phase 3 trial with the KRAS G12C inhibitor garsorasib against standard therapy in KRAS G12C-mutant lung cancer.

## Summary

InxMed, based in Shanghai, develops drugs against the tumour microenvironment and drug resistance. Its lead candidate IN10018 (ifebemtinib) inhibits focal adhesion kinase (FAK), a signal that helps tumours resist KRAS inhibitors and chemotherapy, and is being tested in a phase 3 trial combined with the KRAS G12C inhibitor D-1553 (garsorasib) against standard therapy in non-small-cell lung cancer, as well as in platinum-resistant ovarian cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: InxMed (Shanghai) Co., Ltd.; 应世生物; InxMed (Shanghai); inxmed-shanghai
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.inxmed.com/

## Sources

- Official website: https://www.inxmed.com/
- ClinicalTrials.gov: trials led by InxMed: https://clinicaltrials.gov/search?lead=InxMed

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [IN10018](https://onco.cc/drugs/in10018/)
- trials: [A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation](https://onco.cc/trials/nct07174908/), [IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC](https://onco.cc/trials/nct05994131/), [IN10018 Combination Therapy in Treatment-naïve ES-SCLC](https://onco.cc/trials/nct06030258/), [IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren](https://onco.cc/trials/nct06014528/), [IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer](https://onco.cc/trials/nct05551507/), [IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05827796/)

---
JSON: https://onco.cc/api/v1/entities/inxmed.json